טוען...

Harms of off‐label erythropoiesis‐stimulating agents for critically ill people

BACKGROUND: Anaemia is a common problem experienced by critically‐ill people. Treatment with erythropoiesis‐stimulating agents (ESAs) has been used as a pharmacologic strategy when the blunted response of endogenous erythropoietin has been reported in critically‐ill people. The use of ESAs becomes m...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cochrane Database Syst Rev
Main Authors: Mesgarpour, Bita, Heidinger, Benedikt H, Roth, Dominik, Schmitz, Susanne, Walsh, Cathal D, Herkner, Harald
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley & Sons, Ltd 2017
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6373621/
https://ncbi.nlm.nih.gov/pubmed/28841235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010969.pub2
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!